Outpatient Gastrointestinal Pathogen Panel
Customize your policy alerts
Sign up for Blue Cross Blue Shield - Nebraska Policy V.49 alerts
Get alerted when Policy V.49 changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage and medical necessity for nucleic acid–based gastrointestinal (GI) pathogen panel testing in outpatient and inpatient settings for BCBSNE members, with special coverage provisions for immunocompromised outpatients.
Policy updated to allow outpatient GI panel testing for immunocompromised individuals.
New CPT/PLA code 0369U was added to the codes list (effective 04/01/2023).
Coverage Criteria for GI Pathogen Panels
Inpatient coverage
Covered (scientifically validated) in the inpatient setting
Outpatient — Non-immunocompromised / Investigational
Not covered (considered investigational) when ANY of the following apply
Policy states GI Pathogen Panel for all other outpatient indications is investigational and not medically necessary.
When a specific pathogen is clinically suspected, the policy recommends ordering an individual (single‑plex) diagnostic test rather than a broad multiplex GI pathogen panel. The source document states that, in most instances, individual tests could be ordered when a particular organism is suspected and that broad panels are most appropriate only for a small, not‑well‑defined subset of patients with unusual presentations. Providers should therefore consider targeted testing first and reserve multiplex panels for cases where multiple pathogens are reasonably suspected or when clinical circumstances (for example, atypical presentation) justify simultaneous multi‑target testing.
GI Pathogen Panel testing performed in the outpatient setting for indications other than immunocompromised patients is considered investigational and therefore not medically necessary. The policy explicitly limits outpatient coverage to patients who are immunocompromised (examples provided include transplant recipients, patients receiving cancer treatment, persons with HIV, patients with Crohn's disease, or patients on immunosuppressive therapy).
Indications Considered Medically Necessary
Diagnostic testing for signs and/or symptoms of gastroenteritis in inpatients; diagnostic testing in outpatients who are immunocompromised.
Diagnostic testing for signs and/or symptoms of gastroenteritis in inpatients; diagnostic testing in outpatients who are immunocompromised.
Order should document signs/symptoms of gastroenteritis; when a specific pathogen is suspected, single-target testing may be preferable.
Procedure and PLA Codes
| 0097U | GI PTHGN MULT REV TRANS& PRB TECH 22 TRGT |
| 0369U | IADNA GI PTHGN 31ORG& ID 21 ARG MULT AMP PRB TQ |
| 87505 | INFECTIOUS AGENT DETECTION BY NUCLEIC ACID (DNA OR RNA); GASTROINTESTINAL PATHOGEN, INCLUDES MULTIPLEX REVERSE TRANSCRIPTION, 3-5 TARGETS |
| 87506 | INFECTIOUS AGENT DETECTION BY NUCLEIC ACID (DNA OR RNA); GASTROINTESTINAL PATHOGEN, INCLUDES MULTIPLEX REVERSE TRANSCRIPTION, 6-11 TARGETS |
| 87507 | INFECTIOUS AGENT DETECTION BY NUCLEIC ACID (DNA OR RNA); GASTROINTESTINAL PATHOGEN, INCLUDES MULTIPLEX REVERSE TRANSCRIPTION, 12-25 TARGETS |
Provider Documentation and Authorization Expectations
Prior authorization / claim review expectation for outpatient panels
Testing for outpatient GI pathogen panels will be subject to claim review and must be supported by clinical documentation that meets the policy criteria; outpatient panels are allowable only for immunocompromised patients.
Consider single-pathogen testing first
If a specific pathogen is suspected based on clinical presentation, order a single-target (individual) test instead of a broad multiplex GI panel when clinically appropriate.
- The policy notes individual tests can be ordered in most instances when a specific agent is suspected.
Required clinical documentation
Document signs and/or symptoms of gastroenteritis in the medical record; for outpatient panel testing, also document evidence that the patient is immunocompromised (examples provided in policy).
- Examples of immunocompromised status include transplant recipients, patients receiving cancer treatment, persons with HIV, patients with Crohn's disease, or patients on immunosuppressive therapy for rheumatoid arthritis.
- Documentation should support the high-risk status referenced by the policy; the list of examples is not all-inclusive.
Investigational outpatient indications — denial risk
Outpatient GI pathogen panel testing for indications other than immunocompromised patients is considered investigational and may be denied.
- Routine outpatient testing in patients who are not immunocompromised is not supported by the policy and is a trigger for denial.
Ordering Requirements
Ordering requirements — document gastroenteritis and prefer single-target tests when appropriate
Orders must document clinical signs or symptoms of gastroenteritis; when a specific pathogen is suspected, prefer single-target tests over multiplex panels and use the policy-listed CPT/PLA codes for multiplex testing.
- Document signs/symptoms of gastroenteritis in the order.
- If ordering a multiplex panel, reference the appropriate code(s) (examples: 0097U, 0369U, 87505–87507) as listed in the policy.
- Prefer single-plex testing when a specific pathogen is suspected, per policy guidance.
Frequency Limits
Not Covered / Investigational
Outpatient gastrointestinal pathogen panel testing for patients who are not immunocompromised is considered investigational and is therefore not covered. The policy explains that while multiplex NAAT panels have high sensitivity and can detect bacterial and viral pathogens more rapidly than conventional methods, evidence is insufficient to demonstrate improved health outcomes for general outpatient populations, and routine outpatient use (outside of the immunocompromised subgroup) is a trigger for denial.
Definitions and Test Descriptions
Background
Nucleic acid–based multiplex gastrointestinal pathogen panels use amplified probe techniques to detect nucleic acids (DNA or RNA) from bacterial, viral, and parasitic organisms in stool specimens. These assays identify pathogens directly by their genetic material rather than by culture, microscopy, antigen or toxin assays, or single‑plex PCR alone. Multiplex panels can provide higher sensitivity and more rapid turnaround compared with many conventional stool studies, which may facilitate earlier targeted therapy and infection‑control measures—particularly in high‑risk or immunocompromised patients—but the evidence is insufficient to demonstrate improved health outcomes for routine outpatient use.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.